Australia · Delayed Price · Currency is AUD ALS Limited Earnings Call Transcripts
Fiscal Year 2026
-
Revenue rose 13.3% to AUD 1.7 billion with strong organic growth and margin improvement. Upgraded FY 2026 guidance targets 6%-8% organic growth, with commodities and life sciences both contributing, and robust cash generation supporting investments and dividends.
Fiscal Year 2025
-
A refreshed strategy focuses on disciplined capital allocation, digital transformation, and targeted growth in minerals and environmental sectors. AI and automation are driving efficiency and margin gains, while a strong M&A pipeline and sustainability commitments support long-term value creation.
-
Solid FY2025 results with 16% revenue growth, strategic investments in lab upgrades, and a strong focus on digital transformation and sustainability. Board transitions and remuneration practices were discussed, with shareholders engaging on governance, growth, and technology risks.
-
Strong FY2025 results with 16% revenue growth and robust performance in minerals and life sciences. Major lab upgrades and a AUD 350 million equity raise will support future growth, with FY2026 targeting 5%-7% organic revenue growth and margin expansion.
-
Underlying EBIT rose 2.1% to AUD 250 million, with revenue up 14% to AUD 1.4 billion, driven by strong Life Sciences growth and resilient Minerals margins. Integration of recent acquisitions is progressing, with robust cash flow and a focus on deleveraging and margin improvement.